BACKGROUND: The transforming growth factor-β-signaling pathway has been identified as being involved in colorectal cancer. OBJECTIVE: The aim of this study was to determine how diet and lifestyle factors in combination with genetic variation in the transforming growth factor-β-signaling pathway alters colorectal cancer risk. DESIGN: We used data from 2 population-based case-control studies. PATIENTS: Participants included patients with colon cancer (n = 1574) and controls (n = 1970) and patients with rectal cancer ( n = 791) and controls (n = 999). MAIN OUTCOME MEASURES: The primary outcomes measured were newly diagnosed cases of colon or rectal cancer. RESULTS: Colon and rectal cancer risk increased with the number of at-risk genotypes within the transforming growth factor-β-signaling pathway (OR 3.68, 95% CI 2.74,4.94 for colon cancer; OR 3.89, 95% CI 2.66,5.69 for rectal cancer). A high at-risk lifestyle score also resulted in significant increased risk with number of at-risk lifestyle factors (OR 2.99, 95% CI 2.32,3.85 for colon cancer; OR 3.37, 95% CI 2.24,5.07 for rectal cancer). The combination of high-risk genotype and high-risk lifestyle results in the greatest increase in risk (OR 7.89, 95% CI 4.45,13.96 for colon cancer; OR 8.75, 95% CI 3.66,20.89 for rectal cancer). LIMITATIONS: The study results need validation in other large studies of colon and rectal cancer. CONCLUSIONS: In summary, our data suggest that there is increased colon and rectal cancer risk with increasing number of at-risk genotypes and at-risk lifestyle factors. Although the integrity of the pathway can be diminished by a number of high-risk genotypes, this risk can be offset, in part, by maintaining a healthy lifestyle.
BACKGROUND: The transforming growth factor-β-signaling pathway has been identified as being involved in colorectal cancer. OBJECTIVE: The aim of this study was to determine how diet and lifestyle factors in combination with genetic variation in the transforming growth factor-β-signaling pathway alters colorectal cancer risk. DESIGN: We used data from 2 population-based case-control studies. PATIENTS: Participants included patients with colon cancer (n = 1574) and controls (n = 1970) and patients with rectal cancer ( n = 791) and controls (n = 999). MAIN OUTCOME MEASURES: The primary outcomes measured were newly diagnosed cases of colon or rectal cancer. RESULTS:Colon and rectal cancer risk increased with the number of at-risk genotypes within the transforming growth factor-β-signaling pathway (OR 3.68, 95% CI 2.74,4.94 for colon cancer; OR 3.89, 95% CI 2.66,5.69 for rectal cancer). A high at-risk lifestyle score also resulted in significant increased risk with number of at-risk lifestyle factors (OR 2.99, 95% CI 2.32,3.85 for colon cancer; OR 3.37, 95% CI 2.24,5.07 for rectal cancer). The combination of high-risk genotype and high-risk lifestyle results in the greatest increase in risk (OR 7.89, 95% CI 4.45,13.96 for colon cancer; OR 8.75, 95% CI 3.66,20.89 for rectal cancer). LIMITATIONS: The study results need validation in other large studies of colon and rectal cancer. CONCLUSIONS: In summary, our data suggest that there is increased colon and rectal cancer risk with increasing number of at-risk genotypes and at-risk lifestyle factors. Although the integrity of the pathway can be diminished by a number of high-risk genotypes, this risk can be offset, in part, by maintaining a healthy lifestyle.
Authors: Lin S Chen; Carolyn M Hutter; John D Potter; Yan Liu; Ross L Prentice; Ulrike Peters; Li Hsu Journal: Am J Hum Genet Date: 2010-06-11 Impact factor: 11.025
Authors: Martha L Slattery; Abbie Lundgreen; Jennifer S Herrick; Bette J Caan; John D Potter; Roger K Wolff Journal: Carcinogenesis Date: 2010-11-18 Impact factor: 4.944
Authors: Martha L Slattery; Jennifer S Herrick; Abbie Lundgreen; Roger K Wolff Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-11-10 Impact factor: 4.254
Authors: Gillian K Reeves; Ruth C Travis; Jane Green; Diana Bull; Sarah Tipper; Krys Baker; Valerie Beral; Richard Peto; John Bell; Diana Zelenika; Mark Lathrop Journal: JAMA Date: 2010-07-28 Impact factor: 56.272
Authors: Martha L Slattery; Jennifer Herrick; Karen Curtin; Wade Samowitz; Roger K Wolff; Bette J Caan; David Duggan; John D Potter; Ulrike Peters Journal: Cancer Res Date: 2010-02-02 Impact factor: 12.701
Authors: Yi Zha; Kim Hung Leung; Ka Kin Lo; Wai Yan Fung; Po Wah Ng; Ming-guang Shi; Maurice K H Yap; Shea Ping Yip Journal: Arch Ophthalmol Date: 2009-04
Authors: Lila E Mullany; Jennifer S Herrick; Roger K Wolff; Matthew F Buas; Martha L Slattery Journal: BMC Med Genomics Date: 2016-04-23 Impact factor: 3.063
Authors: Martha L Slattery; Andromahi Trivellas; Andrew J Pellatt; Lila E Mullany; John R Stevens; Roger K Wolff; Jennifer S Herrick Journal: Oncotarget Date: 2017-03-07
Authors: Rachel J J Elands; Colinda C J M Simons; Mona Riemenschneider; Aaron Isaacs; Leo J Schouten; Bas A Verhage; Kristel Van Steen; Roger W L Godschalk; Piet A van den Brandt; Monika Stoll; Matty P Weijenberg Journal: Sci Rep Date: 2017-01-24 Impact factor: 4.379
Authors: Andrew J Pellatt; Lila E Mullany; Jennifer S Herrick; Lori C Sakoda; Roger K Wolff; Wade S Samowitz; Martha L Slattery Journal: J Transl Med Date: 2018-07-09 Impact factor: 5.531
Authors: Colinda C J M Simons; Leo J Schouten; Roger W L Godschalk; Manon van Engeland; Piet A van den Brandt; Frederik J van Schooten; Matty P Weijenberg Journal: Sci Rep Date: 2015-09-18 Impact factor: 4.379